Hepatic InsufficiencyNCT00929032
Liver Transplantation and Reticuloendothelial Clearance Capacity
An observational study of Hepatic Insufficiency and Liver Insufficiency, run by University of Edinburgh at 1 site in United Kingdom.
Trial summary
Study summary: "Liver transplantation and the reticuloendothelial clearance capacity." The purpose of this study is to evaluate the effect of liver transplantation on the immune system. This study will involve the taking of a number of observations but does not involve any treatment, which differs from normal care. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Hepatic Insufficiency, Liver Insufficiency
- What is being tested?
- Nanocoll®
- Type of treatment
- Surgery or procedure
- How many people
- 12 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- Sep 2009to Aug 2010
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients on the waiting list for liver transplantation will be invited to participate in the study and written informed consent will be obtained from each participant. Patients who are undergoing transplantation will be studied before operation, 24 hours after transplantation and 7 days after transplantation.
Who may be able to join
- written informed consent
- chronic liver disease
- listed for transplantation at the Scottish Liver Transplant Unit
Who cannot join
- pregnancy (although pregnant patients would not be listed for liver transplant)
- prisoners
- acute liver failure
- living-related liver transplantation
- multi-organ transplantation or re-transplantation
- ABO incompatible donor
- HIV-positive donor or recipient
- not given informed consent
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
University of Edinburgh
Edinburgh, Midlothian, EH16 4TJ
About this study
Official title: The Impact of Liver Transplantation on Reticuloendothelial Clearance Capacity
Study summary: "Liver transplantation and the reticuloendothelial clearance capacity."
The purpose of this study is to evaluate the effect of liver transplantation on the immune system.
Read more
This study will involve the taking of a number of observations but does not involve any treatment, which differs from normal care. Indications for transplantation are solely based on the best clinical practice, which is usually performed at the department.
The study measures liver function based on the clearance of different "marker" substances by the liver. These substances are given intravenously and their clearance will be measured from bloodstream.
All substances used in this study are registered in the United Kingdom for clinical applications and already used in clinical practice over years. They are safe and without any risk to harm individuals under study. Furthermore no side effects or any symptoms caused by the administration of these substances are expected.
Measurements of liver function are undertaken before transplantation, 1 and 7 days following the transplant. There is no restriction from any of the patient's prescribed medication. All blood samples will be removed from the cannula (drip) and will not require repeated injections. It is hoped that this research will lead to a greater understanding of the effects of liver transplantation on the immune system.
Read the detailed description
Introduction
Liver cells called hepatocytes undertake the most important metabolic functions of the liver. The liver also contains a large number of immune cells called Kupffer cells. These cells act as a filter removing bacteria and other dangerous substances from the blood passing through the liver. Although we know and understand a great deal about how liver cells behave and function after transplant we have no idea what happens to the immune cells in the liver. These immune cells make up 85% of the total body reserves of these cells and serve an important function by clearing bacteria and bacterial products from the blood. A failure of these cells is associated with risk of infection. Infections, blood clotting disorders and many other serious medical issues are typical for patients suffering from chronic liver failure.
This study will use microscopic particles of a human protein called albumin in the form of microspheres to simulate bacteria in the blood. We can detect these microspheres by attaching a radioactive label to the spheres and measuring emission in a detector called a gamma counter. The level of radiation is quite small and similar to a bone scan. We have previously shown that healthy liver rapidly clears these albumin microspheres from the blood. We have also shown previously that after major liver surgery there is a delay in clearance of microspheres, which we believe equates to a poorly functioning innate immune system.
Liver transplantation is the only successful life-extending treatment for patients with chronic liver failure and cirrhosis. During liver transplantation it is known that a proportion of hepatocytes damaged and recover following the transplant. We want to establish the immediate particulate clearance capacity of the liver following transplantation and the pattern of recovery one week later. This is used as a surrogate for liver clearance of bacteria and bacterial products.
We also intend to measure the production of a set of proteins called acute phase proteins, which are produced by the liver and may be important in helping immune cells recognize bacteria. These proteins, also called opsonins, bind to the walls of bacteria and make it easier for immune cells to attach to the bacteria and eat them.
We also want to find out if there is any difference between non-marginal and marginal liver grafts and their reticuloendothelial clearance capacity. This study may provide important information regarding the need for post-operative antibiotics and prevention of infection in this patient group.
This research will be the first of its kind to address this issue in this vulnerable group of patients and no study has ever looked at the effect of transplantation on the immune cells of the liver. This study will investigate the ability of the liver to clear particles (albumin microspheres) from the blood and will monitor the recover and improvement in function of these cells over a period of time.
Results of any pilot studies
A study also from the eLISTER group (Edinburgh liver injury in surgery and transplantation experimental research) about the effect of major liver resection on innate immunity to bacterial endotoxin was approved by Lothian research Ethics Committee LREC/2002/1/31. This trial was performed between May 2003 and 2005. This study looked at the adaptive response of the reticuloendothelial system to major liver resection. We found a strong correlation between clearance of albumin microspheres and ICG (indocyanine green clearance), supporting the assertion that hepatocellular function and RES phagocytosis are related if only in terms of liver volume. We also demonstrated marked defects in RES phagocytosis in patients with chronic liver disease or normal liver function, who had undergone a major liver resection.
Validation of technique of measurement of phagocytic clearance of Tc-99m labelled (Nanocoll®) microaggregated human albumin To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies. It has been shown in several studies that this is a reliable method to estimate RES phagocytosis activity. By measuring the plasma radioactivity disappearance rate instead of doing imaging studies a radioactivity dose of less than 15 MBq is sufficient to determine 99mTc plasma clearance accurately. Disappearance of 99mTc blood activity will be measured serially at 3-minutes intervals to 30 minutes, at 10-minutes intervals to 60 minutes and at 20-minutes intervals to 120 minutes. Three half-life times required for the 99mTc albumin microspheres counting rate to fall from 100% to 50%, from 50% to 25% and from 25% to 12.5% of the value obtained at three minutes after injection are noted and the mean half-life and standard deviation, expressing the microspheres blood clearance, is calculated. To determine the possibly non-linear nature of albumin microspheres clearance over time the area under the curve will be calculated over the observation time using integral function. Mean half-life of albumin microspheres in the blood and area under the curve at day 1 and day 7 after transplantation will be expressed as a percentage of preoperative values and compared between individuals and patient groups. We hypothesize that the phagocytosis activity of marginal compared to good liver grafts is significantly impaired after liver transplantation due to the decreased number of phagocytes as well as due to the decreased synthesis of substances which usually facilitates phagocytosis. If this hypothesis is true, the RES phagocytosis activity in the marginal grafts should be significantly increased after liver transplantation and should be comparable to the RES phagocytosis activity of non-marginal grafts.
Aims
This project will test the hypothesis that liver transplantation of normal and marginal grafts results in a significant impairment of innate immunity to bacterial endotoxin.
We intend to characterise the nature or reticuloendothelial clearance impairment following liver transplantation and its recovery on marginal and non-marginal grafts. We also wish to correlate clearance capacity with measures of hepatocyte injury (ALT/AST) and liver dysfunction score to establish whether the two processes are independent or related.
In this regard we will compare marginal and non-marginal organs and the relationship between reticuloendothelial cell dysfunction and cold ischemic time. Reticuloendothelial clearance capacity will also be related to evidence of clinical infection in the postoperative course.
Research questions - Hypotheses
- Liver transplantation results in a significant impairment of innate immunity to bacterial endotoxin.
II. The degree of impairment in innate immunity to endotoxin is directly related to the functional status of the liver graft. (Patients undergoing liver transplantation with non-marginal and marginal grafts will be compared).
III. To establish whether there is any correlation between liver cell (hepatocyte) injury and immune cell (Kupffer cell) injury after transplantation.
IV. To establish the effect of liver transplantation on serum expression of acute phase protein opsonins.
- Conditions
- Hepatic Insufficiency, Liver Insufficiency
- Being tested
- Nanocoll®
- Keywords
- Liver Transplantation, Immunosystem of the Liver, Marginal and Non-marginal grafts
- Medical subject headings
- Hepatic Insufficiency, Margins of Excision
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nanocoll®Radiation
To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
| Study group | Role | What they receive |
|---|---|---|
| Liver transplant recipient | Liver transplant recipient Receives: Radiation: Nanocoll® |
What is being measured
The primary outcome is the main question the study is designed to answer.
We want to establish the immediate particulate clearance capacity of the liver following transplantation and the pattern of recovery one week later. This is used as a surrogate for liver clearance of bacteria and bacterial products.
Measured: 7 days
Secondary outcomes (2)
To establish whether there is any correlation between liver cell (hepatocyte) injury and immune cell (Kupffer cell) injury after transplantation.
Measured: 7 days
To establish the effect of liver transplantation on serum expression of acute phase protein opsonins.
Measured: 7 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jun 2009 (estimated)
- Study startSep 2009
- Primary completionJul 2010
- Study completionAug 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Hepatic InsufficiencyStudies of the same condition, open and under way.
- More trials run by University of EdinburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 12 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Edinburgh
- Sponsor type
- University, hospital or other
- Collaborators
- NHS Lothian, European Society of Organ Transplantation
- Investigators
- Stephen J Wigmore, Prof, MD, Principal investigator, University of Edinburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00929032
- Sponsor's protocol ID
- NanospheresLiverEdinburgh09
- Status last verified
- Oct 2010
- First submitted
- 24 Jun 2009
- Last updated
- 20 Oct 2010
- Results posted
- No
- Data monitoring committee
- No
Publications
Schindl MJ, Millar AM, Redhead DN, Fearon KC, Ross JA, Dejong CH, Garden OJ, Wigmore SJ. The adaptive response of the reticuloendothelial system to major liver resection in humans. Ann Surg. 2006 Apr;243(4):507-14. doi: 10.1097/01.sla.0000205826.62911.a7.
PubMed 16552202Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000 Aug 3;343(5):338-44. doi: 10.1056/NEJM200008033430506. No abstract available.
PubMed 10922424
Study at a glance
From the registry record, last updated by the sponsor on 20 Oct 2010. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Impact of Liver Transplantation on Reticuloendothelial Clearance Capacity
- ClinicalTrials.gov ID
- NCT00929032
- Acronym / sponsor ID
- NanospheresLiverEdinburgh09
- Conditions
- Hepatic Insufficiency, Liver Insufficiency
- Keywords
- Liver Transplantation, Immunosystem of the Liver, Marginal and Non-marginal grafts
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 12 participants (estimated)
- Lead sponsor
- University of EdinburghUniversity, hospital or other
- Collaborators
- NHS Lothian, European Society of Organ Transplantation
- Study start
- Sep 2009
- Primary completion
- Jul 2010 (actual)
- Study completion
- Aug 2010 (actual)
- First posted
- 26 Jun 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Study summary: "Liver transplantation and the reticuloendothelial clearance capacity."
The purpose of this study is to evaluate the effect of liver transplantation on the immune system.
This study will involve the taking of a number of observations but does not involve any treatment, which differs from normal care. Indications for transplantation are solely based on the best clinical practice, which is usually performed at the department.
The study measures liver function based on the clearance of different "marker" substances by the liver. These substances are given intravenously and their clearance will be measured from bloodstream.
All substances used in this study are registered in the United Kingdom for clinical applications and already used in clinical practice over years. They are safe and without any risk to harm individuals under study. Furthermore no side effects or any symptoms caused by the administration of these substances are expected.
Measurements of liver function are undertaken before transplantation, 1 and 7 days following the transplant. There is no restriction from any of the patient's prescribed medication. All blood samples will be removed from the cannula (drip) and will not require repeated injections. It is hoped that this research will lead to a greater understanding of the effects of liver transplantation on the immune system.
Detailed description
Introduction
Liver cells called hepatocytes undertake the most important metabolic functions of the liver. The liver also contains a large number of immune cells called Kupffer cells. These cells act as a filter removing bacteria and other dangerous substances from the blood passing through the liver. Although we know and understand a great deal about how liver cells behave and function after transplant we have no idea what happens to the immune cells in the liver. These immune cells make up 85% of the total body reserves of these cells and serve an important function by clearing bacteria and bacterial products from the blood. A failure of these cells is associated with risk of infection. Infections, blood clotting disorders and many other serious medical issues are typical for patients suffering from chronic liver failure.
This study will use microscopic particles of a human protein called albumin in the form of microspheres to simulate bacteria in the blood. We can detect these microspheres by attaching a radioactive label to the spheres and measuring emission in a detector called a gamma counter. The level of radiation is quite small and similar to a bone scan. We have previously shown that healthy liver rapidly clears these albumin microspheres from the blood. We have also shown previously that after major liver surgery there is a delay in clearance of microspheres, which we believe equates to a poorly functioning innate immune system.
Liver transplantation is the only successful life-extending treatment for patients with chronic liver failure and cirrhosis. During liver transplantation it is known that a proportion of hepatocytes damaged and recover following the transplant. We want to establish the immediate particulate clearance capacity of the liver following transplantation and the pattern of recovery one week later. This is used as a surrogate for liver clearance of bacteria and bacterial products.
We also intend to measure the production of a set of proteins called acute phase proteins, which are produced by the liver and may be important in helping immune cells recognize bacteria. These proteins, also called opsonins, bind to the walls of bacteria and make it easier for immune cells to attach to the bacteria and eat them.
We also want to find out if there is any difference between non-marginal and marginal liver grafts and their reticuloendothelial clearance capacity. This study may provide important information regarding the need for post-operative antibiotics and prevention of infection in this patient group.
This research will be the first of its kind to address this issue in this vulnerable group of patients and no study has ever looked at the effect of transplantation on the immune cells of the liver. This study will investigate the ability of the liver to clear particles (albumin microspheres) from the blood and will monitor the recover and improvement in function of these cells over a period of time.
Results of any pilot studies
A study also from the eLISTER group (Edinburgh liver injury in surgery and transplantation experimental research) about the effect of major liver resection on innate immunity to bacterial endotoxin was approved by Lothian research Ethics Committee LREC/2002/1/31. This trial was performed between May 2003 and 2005. This study looked at the adaptive response of the reticuloendothelial system to major liver resection. We found a strong correlation between clearance of albumin microspheres and ICG (indocyanine green clearance), supporting the assertion that hepatocellular function and RES phagocytosis are related if only in terms of liver volume. We also demonstrated marked defects in RES phagocytosis in patients with chronic liver disease or normal liver function, who had undergone a major liver resection.
Validation of technique of measurement of phagocytic clearance of Tc-99m labelled (Nanocoll®) microaggregated human albumin To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies. It has been shown in several studies that this is a reliable method to estimate RES phagocytosis activity. By measuring the plasma radioactivity disappearance rate instead of doing imaging studies a radioactivity dose of less than 15 MBq is sufficient to determine 99mTc plasma clearance accurately. Disappearance of 99mTc blood activity will be measured serially at 3-minutes intervals to 30 minutes, at 10-minutes intervals to 60 minutes and at 20-minutes intervals to 120 minutes. Three half-life times required for the 99mTc albumin microspheres counting rate to fall from 100% to 50%, from 50% to 25% and from 25% to 12.5% of the value obtained at three minutes after injection are noted and the mean half-life and standard deviation, expressing the microspheres blood clearance, is calculated. To determine the possibly non-linear nature of albumin microspheres clearance over time the area under the curve will be calculated over the observation time using integral function. Mean half-life of albumin microspheres in the blood and area under the curve at day 1 and day 7 after transplantation will be expressed as a percentage of preoperative values and compared between individuals and patient groups. We hypothesize that the phagocytosis activity of marginal compared to good liver grafts is significantly impaired after liver transplantation due to the decreased number of phagocytes as well as due to the decreased synthesis of substances which usually facilitates phagocytosis. If this hypothesis is true, the RES phagocytosis activity in the marginal grafts should be significantly increased after liver transplantation and should be comparable to the RES phagocytosis activity of non-marginal grafts.
Aims
This project will test the hypothesis that liver transplantation of normal and marginal grafts results in a significant impairment of innate immunity to bacterial endotoxin.
We intend to characterise the nature or reticuloendothelial clearance impairment following liver transplantation and its recovery on marginal and non-marginal grafts. We also wish to correlate clearance capacity with measures of hepatocyte injury (ALT/AST) and liver dysfunction score to establish whether the two processes are independent or related.
In this regard we will compare marginal and non-marginal organs and the relationship between reticuloendothelial cell dysfunction and cold ischemic time. Reticuloendothelial clearance capacity will also be related to evidence of clinical infection in the postoperative course.
Research questions - Hypotheses
- Liver transplantation results in a significant impairment of innate immunity to bacterial endotoxin.
II. The degree of impairment in innate immunity to endotoxin is directly related to the functional status of the liver graft. (Patients undergoing liver transplantation with non-marginal and marginal grafts will be compared).
III. To establish whether there is any correlation between liver cell (hepatocyte) injury and immune cell (Kupffer cell) injury after transplantation.
IV. To establish the effect of liver transplantation on serum expression of acute phase protein opsonins.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Liver transplant recipient | – | Radiation: Nanocoll®Liver transplant recipient |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients on the waiting list for liver transplantation will be invited to participate in the study and written informed consent will be obtained from each participant. Patients who are undergoing transplantation will be studied before operation, 24 hours after transplantation and 7 days after transplantation.
Key inclusion criteria (3 listed)
- written informed consent
- chronic liver disease
- listed for transplantation at the Scottish Liver Transplant Unit
Key exclusion criteria (8 listed)
- pregnancy (although pregnant patients would not be listed for liver transplant)
- prisoners
- acute liver failure
- living-related liver transplantation
- multi-organ transplantation or re-transplantation
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Nanocoll®To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies. | Radiation | Liver transplant recipient |
Primary outcome
We want to establish the immediate particulate clearance capacity of the liver following transplantation and the pattern of recovery one week later. This is used as a surrogate for liver clearance of bacteria and bacterial products.
Time frame: 7 days
2 secondary outcomes
To establish whether there is any correlation between liver cell (hepatocyte) injury and immune cell (Kupffer cell) injury after transplantation.
Time frame: 7 days
To establish the effect of liver transplantation on serum expression of acute phase protein opsonins.
Time frame: 7 days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Oct 2010.
- Background: PubMed 16552202Schindl MJ, Millar AM, Redhead DN, Fearon KC, Ross JA, Dejong CH, Garden OJ, Wigmore SJ. The adaptive response of the reticuloendothelial system to major liver resection in humans. Ann Surg. 2006 Apr;243(4):507-14. doi: 10.1097/01.sla.0000205826.62911.a7.
- Background: PubMed 10922424Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med. 2000 Aug 3;343(5):338-44. doi: 10.1056/NEJM200008033430506. No abstract available.
Related trials for Hepatic Insufficiency
Not yet recruiting
Double Plasma Separation and Adsorption in Acute-on-Chronic Liver Failure (DPMAS-ACLF Trial)
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruiting
Vitamin C for Acute Kidney Injury in ACLF With Septic Shock: A Randomized Controlled Trial
Acute-on-Chronic Liver Failure (ACLF)
Not yet recruitingPhase 1
A Study to Assess the Pharmacokinetics and Safety of Revumenib in Participants With Advanced Cancer and Hepatic or Renal Impairment
Relapsed/Refractory (R/R) Hematologic Malignancies, Acute Leukemia
Active, not recruiting
LiverPAL: A Trial of Inpatient Palliative Care for Patients With Advanced Liver Disease
Liver Disease Chronic, End Stage Liver DIsease
RecruitingObservational study
Establishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe
End-stage Liver Disease (ESLD), Acute Liver Failure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Stephen J Wigmore, Prof, MD principal investigator
University of Edinburgh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hepatic Insufficiency and Liver Insufficiency, run by University of Edinburgh at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Oct 2010. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
We want to establish the immediate particulate clearance capacity of the liver following transplantation and the pattern of recovery one week later. This is used as a surrogate for liver clearance of bacteria and bacterial products. (time frame: 7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00929032, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Oct 2010.